Global Markets
GSK (GSK LN) are expecting three times yearly Cibanooga launch in 2028 with phase three study on track and also anticipates new standard of care that doubles provider administration capacity while highly desired by patients and physicians
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
